Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization

Reuters

Aug 28

Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization

Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562470435"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562470435\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562470435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 13:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562470435","market":"fut","top_or_hot":-1,"title":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-28 13:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL9nX8lT:1","article_id":"2562470435","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562470435","pubTimestamp":1756357637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization. Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide , with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO ystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","VRCA":"Verrica Pharmaceuticals Inc."},"translate_title":"Lytix Biopharma AS宣布2025年下半年具有里程碑意义，Ruxotemitide临床试验取得进展，并为未来商业化做好战略准备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9},"content_text":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    \n\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}